Compare Stocks → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSEARCA:FRNNYSEARCA:GFINNYSEARCA:GMANNASDAQ:GRI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFRNInvesco Frontier Markets ETF$14.28+0.8%$14.28$13.30▼$14.84$51.98MN/A51,626 shs37,400 shsGFINGoldman Sachs Finance Reimagined ETF$67.11+0.2%$67.11$38.81▼$68.70$52.01MN/A4,855 shs1,800 shsGMANGoldman Sachs Manufacturing Revolution ETF$77.92+0.3%$77.92$37.01▼$77.95$52.60MN/A4,156 shs1,600 shsGRIGRI Bio0.76-2.1%1.190.75▼115.50$494K-1.79743,371 shs126,900 shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFRNInvesco Frontier Markets ETF0.00%0.00%0.00%0.00%0.00%GFINGoldman Sachs Finance Reimagined ETF0.00%0.00%0.00%0.00%+0.00%GMANGoldman Sachs Manufacturing Revolution ETF0.00%0.00%0.00%0.00%-0.01%GRIGRI Bio-2.06%-3.31%-6.42%-71.80%+75,999,900.00%Central Banks Preparing for US Dollar Collapse? (Ad)China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFRNInvesco Frontier Markets ETFN/AN/AN/AN/AN/AN/AN/AN/AGFINGoldman Sachs Finance Reimagined ETFN/AN/AN/AN/AN/AN/AN/AN/AGMANGoldman Sachs Manufacturing Revolution ETFN/AN/AN/AN/AN/AN/AN/AN/AGRIGRI Bio0.6585 of 5 stars0.04.00.00.03.00.80.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFRNInvesco Frontier Markets ETF0.00N/AN/AN/AGFINGoldman Sachs Finance Reimagined ETF0.00N/AN/AN/AGMANGoldman Sachs Manufacturing Revolution ETF0.00N/AN/AN/AGRIGRI BioN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFRNInvesco Frontier Markets ETFN/AN/AN/AN/AN/AN/AGFINGoldman Sachs Finance Reimagined ETFN/AN/AN/AN/AN/AN/AGMANGoldman Sachs Manufacturing Revolution ETFN/AN/AN/AN/AN/AN/AGRIGRI BioN/AN/AN/AN/A38.62 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFRNInvesco Frontier Markets ETFN/AN/A0.00∞N/AN/AN/AN/AN/AGFINGoldman Sachs Finance Reimagined ETFN/AN/A0.00∞N/AN/AN/AN/AN/AGMANGoldman Sachs Manufacturing Revolution ETFN/AN/A0.00∞N/AN/AN/AN/AN/AGRIGRI Bio-$7.02M-81.48N/A∞N/AN/A-595.60%-315.73%3/29/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFRNInvesco Frontier Markets ETF$0.463.22%N/AN/AN/AGFINGoldman Sachs Finance Reimagined ETF$0.500.75%N/AN/AN/AGMANGoldman Sachs Manufacturing Revolution ETF$0.410.53%N/AN/AN/AGRIGRI BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFRNInvesco Frontier Markets ETFN/AN/AN/AGFINGoldman Sachs Finance Reimagined ETFN/AN/AN/AGMANGoldman Sachs Manufacturing Revolution ETFN/AN/AN/AGRIGRI BioN/A2.012.01OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFRNInvesco Frontier Markets ETFN/AGFINGoldman Sachs Finance Reimagined ETFN/AGMANGoldman Sachs Manufacturing Revolution ETFN/AGRIGRI Bio33.95%Insider OwnershipCompanyInsider OwnershipFRNInvesco Frontier Markets ETFN/AGFINGoldman Sachs Finance Reimagined ETFN/AGMANGoldman Sachs Manufacturing Revolution ETFN/AGRIGRI Bio16.82%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableFRNInvesco Frontier Markets ETFN/A3.64 millionN/ANot OptionableGFINGoldman Sachs Finance Reimagined ETFN/A775,000N/ANot OptionableGMANGoldman Sachs Manufacturing Revolution ETFN/A675,000N/ANot OptionableGRIGRI Bio1650,000537,000Not OptionableGMAN, GFIN, FRN, and GRI HeadlinesSourceHeadlineTamil Nadu Newsprint & Papers Share Pricebusiness-standard.com - March 28 at 7:19 PMSteven Ehrlich donates professional archive to Architecture and Design Collection at UCSB’s AD&A Museumarchpaper.com - March 28 at 7:19 PMGRI Bio to Present at the MedInvest Biotech & Pharma Investor Conferenceglobenewswire.com - March 28 at 9:00 AMUCSB Art Museum Collection adds Archive of Modernist Architect Steven Ehrlichnoozhawk.com - March 18 at 9:11 PMProminent Modernist Steven Ehrlich Adds Architectural Archives to UC Santa Barbara Art Museumindependent.com - March 15 at 8:03 PMGRI Bio, Inc.: GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulatorsfinanznachrichten.de - March 14 at 1:50 PMGRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulatorsfinance.yahoo.com - March 14 at 8:50 AMGRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulatorsglobenewswire.com - March 14 at 8:45 AMGRI Bio, Inc.: GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdomfinanznachrichten.de - March 4 at 12:43 PMGRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdomglobenewswire.com - March 4 at 8:30 AMTop 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)benzinga.com - February 23 at 7:50 AMGRI Bio: Entry Into A Material Definitive Agreement, Other Eventscbonds.com - February 5 at 2:06 PMGRI Bio Launches Major Securities Public Offeringmsn.com - February 3 at 2:55 PMGRI Bio prices 5M shares at $1.10 in public offeringmsn.com - February 2 at 12:29 PMGRI Bio Shares Drop After Stock Offering Prices Below Thursday's Closemarketwatch.com - February 2 at 12:29 PMGRI Bio Announces Pricing Of $5.5 Mln Public Offering, Stock Downmarkets.businessinsider.com - February 2 at 12:29 PMWhy Is GRI Bio (GRI) Stock Down 21% Today?investorplace.com - February 2 at 11:07 AMSamsung Galaxy Fit3 tüm ayrıntılarıyla belli oldu: İşte özellikleridonanimhaber.com - January 31 at 12:56 PMGRI Bio, Inc.: GRI Bio Announces Reverse Stock Splitfinanznachrichten.de - January 26 at 7:25 PMGRI Bio's board OKs 1-for-7 reverse stock splitmsn.com - January 26 at 7:25 PMGRI Bio Announces Reverse Stock Splitfinance.yahoo.com - January 26 at 7:25 PMGRI Bio: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listingcbonds.com - January 10 at 3:34 PMGRI Bio, Inc. (GRI) Stock Historical Prices & Data - Yahoo Financefinance.yahoo.com - January 9 at 1:17 PMGalore Appoints a New Chairman and New Directorbr.advfn.com - January 6 at 3:27 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsInvesco Frontier Markets ETFNYSEARCA:FRNGuggenheim Frontier Markets ETF (the Fund), formerly Claymore/BNY Mellon Frontier Markets ETF, seeks investment results that correspond generally to the performance of an equity index called Bank of New York Mellon New Frontier DR Index (the Frontier Index). The Fund will invest at least 80% of its total assets in American depositary receipts (ADRs) and global depositary receipts (GDRs) that consists of the Index or in the stocks underlying such ADRs and GDRs. The Fund also will invest at least 80% of its total assets in securities of issuers from Frontier Market countries. The Frontier Index tracks the performance of depositary receipts, in ADR or GDR form, that trade on the London Stock Exchange (LSE), New York Stock Exchange (NYSE), NYSE Arca, Inc. (NYSE Arca), NYSE AMEX, and Nasdaq Stock Market (NASDAQ) of companies from countries that are defined as the Frontier Market. Guggenheim Funds Investment Advisors, LLC is the investment adviser of the Fund.Goldman Sachs Finance Reimagined ETFNYSEARCA:GFINGoldman Sachs Manufacturing Revolution ETFNYSEARCA:GMANGRI BioNASDAQ:GRIGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.